Vendor GDPR in Clinical Trials: What the IQVIA CNIL Ruling Changes for Sponsors and Healthtech Companies

Why the CNIL Ruling Matters Beyond IQVIA

The IQVIA decision is the first CNIL sanction in 2026 that explicitly targets the gap between how vendors describe their data and how regulators classify it. IQVIA Operations France runs two authorised health data warehouses, LRX and EMR, fed by data from approximately 14,000 pharmacies and several thousand doctors. The CNIL found four classes of failure: inadequate connection log monitoring, missing multi factor authentication, inaccurate patient information notices, and a complete absence of information to pharmacy customers that their prescription data was being transmitted to IQVIA. The fine was set at €5 million.

The reasoning matters more than the amount. The CNIL ruled that the data in the warehouses was pseudonymous, not anonymous, because individuals remained re identifiable through combinations of unique identifiers and publicly available information. That single qualification is what brought the full GDPR machinery to bear: security obligations under Article 32, information obligations under Articles 13 and 14, and the authorisation conditions attached to health data warehouses under French law.

For clinical trials and healthtech, this is not an IQVIA specific problem. Sponsors regularly receive analytics, real world evidence and patient registries from vendors that present the data as anonymised. CROs run safety reporting pipelines fed by partially de identified datasets. Healthtech companies build clinical decision support tools on data that vendors claim falls outside GDPR scope. The CNIL has now drawn a line, and that line cuts through a significant share of the vendor relationships in the sector.

Focus: The Example of France - CNIL’s Anonymisation Test

The CNIL applies the Article 29 Working Party WP216 three criterion test: individuation, linkability, and inference. If any one of the three is technically possible, the dataset is pseudonymous and GDPR applies in full. In the IQVIA case, the warehouses retained unique identifiers and time stamps that, combined with prescription patterns and public information, allowed re identification. The fact that IQVIA itself did not perform re identification was deemed irrelevant; the possibility was sufficient.

The Pseudonymous Versus Anonymous Test, Restated

Article 4(5) GDPR defines pseudonymisation as the processing of personal data in such a manner that the data can no longer be attributed to a specific data subject without the use of additional information, provided that such additional information is kept separately. Anonymisation, by contrast, requires that re identification be irreversible by any means reasonably likely to be used, taking account of objective factors such as the cost and time required, the technology available, and the data accessible to third parties.

The practical difference is dramatic. Pseudonymous data is personal data under Article 4(1) and triggers the full set of obligations: legal basis under Articles 6 and 9, information notices under Articles 13 and 14, security under Article 32, transfer rules under Chapter V, and so on. Anonymous data falls outside GDPR entirely. The pressure on vendors to label data as anonymised is therefore intense, and the CNIL ruling makes clear that the label alone has no legal value.

Pseudonymous, Anonymous, and the Test That Decides

Five Questions to Ask Every Vendor Today

Following the IQVIA ruling, iliomad recommends that sponsors and healthtech operators put five questions to every vendor that processes data described as anonymised or de identified. The answers should be in writing and form part of the next contract amendment or vendor assessment cycle.

• Has the WP216 Test Been Applied. Ask for the documented analysis of individuation, linkability and inference, performed on the actual dataset shared with you, not on a hypothetical fully aggregated dataset.

• Which Identifiers Are Retained. Patient identifiers, prescription identifiers, device serial numbers, IP addresses, browser fingerprints and time stamps all count. The presence of any of them is a strong indicator of pseudonymisation.

• Who Else Holds the Additional Information. If the vendor, a sub processor, the originating site or a public source could combine fields to re identify, the data is pseudonymous in your hands.

• What Security Measures Apply. The CNIL listed multi factor authentication and connection log monitoring as expected baselines. Ask for evidence, not for assurances.

• Have Data Subjects Been Informed. Patient information notices, pharmacist notices, site staff notices and ICF wording all need to reflect the vendor flow accurately. The IQVIA ruling penalised omissions, not only inaccuracies.

Focus: The Example of European Union - CTIS and Vendor Disclosure

Under the EU Clinical Trials Regulation 536/2014 and the CTIS publication framework, sponsors disclose the vendors that process trial data. Where a vendor receives pseudonymous data, the legal basis under Article 6 and the safeguards under Article 89 GDPR must be documented and consistent across the protocol, the CTIS submission, the ICF and the vendor contract. Inconsistencies between these four documents are now the most common audit finding in iliomad’s gap assessments.

Where Clinical Trial and Healthtech Contracts Typically Fail

Reviewing the IQVIA case alongside the contract patterns iliomad sees across its life sciences client base, the same five contractual weaknesses recur.

First, vague qualification clauses. Contracts that state the vendor processes anonymised data without defining the standard against which anonymity is measured. After IQVIA, such clauses provide no defence.

Second, missing controller and processor allocation. Where the vendor builds a derivative dataset for its own commercial purposes, typical for real world evidence platforms, the vendor is a controller, not a processor. The contract should reflect that fact under Article 26 or as a controller to controller arrangement, with the corresponding obligations.

Third, security commitments stated as policies, not as testable controls. Article 32 GDPR requires technical and organisational measures appropriate to the risk. After IQVIA, the appropriate baseline includes multi factor authentication, connection log monitoring, encryption at rest and in transit, and periodic penetration testing. These should be in the contract as measurable obligations, with the right to audit.

Fourth, sub processor opacity. Vendors that subcontract analytics, hosting or AI training without flowing down the obligations create the same exposure as IQVIA in relation to its own operational chain. Sponsors should require sub processor lists, prior authorisation of additions and back to back terms.

Fifth, missing data subject information loop. The contract should require the vendor to support the sponsor’s transparency obligations, including providing accurate text for patient information notices and ICFs.

Focus: The Example of United Kingdom - ICO’s Parallel Position

The Information Commissioner’s Office has applied the same analytical framework as the CNIL in its anonymisation, pseudonymisation and privacy enhancing technologies guidance, finalised in 2023. UK sponsors and CROs should expect that a CNIL style ruling could be replicated by the ICO on UK GDPR grounds, particularly where the vendor processes data from NHS sources or CPRD linked datasets.

The iliomad Three Step Requalification Framework

Following the IQVIA ruling, iliomad applies a three step requalification framework to any data flow involving a vendor that processes patient, prescription, device or research data. Sponsors and healthtech operators can use the same framework as a self assessment.

Step 1, Requalify the Data

Apply the WP216 test to the dataset actually transferred to or received from the vendor. Document the answer. If pseudonymous, proceed to Step 2. If anonymous, retain the documented analysis as evidence; the burden of proof under Article 5(2) GDPR is on the controller, and a label is not evidence.

Step 2, Requalify the Roles

Determine whether the vendor is a processor, acting on the controller’s instructions only, a joint controller, jointly determining purposes and means with the sponsor or healthtech operator, or an independent controller, using the data for its own commercial purposes such as building proprietary models or RWE datasets. Each role triggers different contractual obligations under Articles 26 and 28.

Step 3, Requalify the Contract

Bring the contract in line with the requalified data and roles. This usually means adding or replacing the data protection schedule, updating the security annex with measurable controls, adding sub processor controls, clarifying transfer mechanisms under Chapter V, and refreshing the patient and site information notices to reflect the actual flow.

Focus: The Example of Germany - DSK Position on Health Data Warehouses

The German Datenschutzkonferenz, the standing conference of federal and Land data protection authorities, has consistently treated health data warehouses fed by pharmacy or doctor data as pseudonymous processing requiring an Article 9(2)(j) GDPR legal basis combined with appropriate safeguards under §27 BDSG. The CNIL ruling aligns the French and German positions, which had previously diverged on the threshold of acceptable re identification risk.

What Sponsors and Healthtech Operators Should Do Next

The IQVIA decision is a regulatory inflexion point. The data labels in vendor contracts no longer settle the question. The cost of getting this wrong is now measurable in millions, and the cost of getting it right is a focused review of the vendor stack, the contract estate and the transparency layer.

iliomad’s vendor and DPA review service is designed to deliver this requalification work in a single sprint per vendor, with documented WP216 analysis, redlined contract amendments, refreshed patient information notices and a remediation roadmap. Sponsors and healthtech operators with vendor stacks of any size are welcome to contact us for a scoping call.

‍

‍